BACKGROUND: Neutrophil to lymphocyte ratio (NLR) is widely used as a marker of inflammation and an indicator of cardiovascular outcomes in patients with coronary artery disease. However, its prognostic value in peritoneal dialysis (PD) patients is still unknown. METHODS: We studied 138 newly started PD patients and 60 healthy controls at the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Baseline NLR as well as demographic, clinical, and biochemical parameters were recorded. All patients were followed up until March 2011 to evaluate mortality as the primary outcome. Overall and cardiovascular disease-free survival rates were compared according to NLR level. Multivariate analysis was performed to assess the prognostic value of NLR. RESULTS: Baseline NLR levels (mean 3.5 ± 1.6) were significantly increased in PD patients compared to healthy controls (mean 1.5 ± 0.5; P < 0.001). Patients with higher NLR had a higher mortality rate compared with patients with lower NLR (51.5% vs 22.9%; P = 0.006). The 1-year and 3-year overall survival rates were 86.6% and 65.9% for patients with higher NLR compared with 97% and 85.1% for patients with lower NLR (P = 0.006). Patients with higher NLR also showed a higher cardiovascular mortality rate, compared with patients with lower NLR (38% vs 7.6%; P = 0.003). The 1-year and 3-year cardiovascular event-free survival rates were 90.7% and 81.9% for patients with higher NLR, compared with 98.6% and 95.1% for patients with lower NLR. Multivariate analysis showed high NLR value was an independent risk factor for all-cause and cardiovascular mortality. CONCLUSION: Neutrophil to lymphocyte ratio is a strong predictor for overall and cardiovascular mortality in PD patients.
BACKGROUND: Neutrophil to lymphocyte ratio (NLR) is widely used as a marker of inflammation and an indicator of cardiovascular outcomes in patients with coronary artery disease. However, its prognostic value in peritoneal dialysis (PD) patients is still unknown. METHODS: We studied 138 newly started PDpatients and 60 healthy controls at the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Baseline NLR as well as demographic, clinical, and biochemical parameters were recorded. All patients were followed up until March 2011 to evaluate mortality as the primary outcome. Overall and cardiovascular disease-free survival rates were compared according to NLR level. Multivariate analysis was performed to assess the prognostic value of NLR. RESULTS: Baseline NLR levels (mean 3.5 ± 1.6) were significantly increased in PDpatients compared to healthy controls (mean 1.5 ± 0.5; P < 0.001). Patients with higher NLR had a higher mortality rate compared with patients with lower NLR (51.5% vs 22.9%; P = 0.006). The 1-year and 3-year overall survival rates were 86.6% and 65.9% for patients with higher NLR compared with 97% and 85.1% for patients with lower NLR (P = 0.006). Patients with higher NLR also showed a higher cardiovascular mortality rate, compared with patients with lower NLR (38% vs 7.6%; P = 0.003). The 1-year and 3-year cardiovascular event-free survival rates were 90.7% and 81.9% for patients with higher NLR, compared with 98.6% and 95.1% for patients with lower NLR. Multivariate analysis showed high NLR value was an independent risk factor for all-cause and cardiovascular mortality. CONCLUSION: Neutrophil to lymphocyte ratio is a strong predictor for overall and cardiovascular mortality in PDpatients.
Authors: Trinh B Pifer; Keith P McCullough; Friedrich K Port; David A Goodkin; Bradley J Maroni; Philip J Held; Eric W Young Journal: Kidney Int Date: 2002-12 Impact factor: 10.612
Authors: Allan J Collins; Robert N Foley; Charles Herzog; Blanche Chavers; David Gilbertson; Areef Ishani; Bertram Kasiske; Jiannong Liu; Lih-Wen Mau; Marshall McBean; Anne Murray; Wendy St Peter; Haifeng Guo; Sally Gustafson; Qi Li; Shuling Li; Suying Li; Yi Peng; Yang Qiu; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Changchun Wang; Eric Weinhandl; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frederick Dalleska; Frank Daniels; Stephan Dunning; James Ebben; Eric Frazier; Christopher Hanzlik; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa Journal: Am J Kidney Dis Date: 2011-01 Impact factor: 8.860
Authors: David Wayne Johnson; Kathryn Joan Wiggins; Kirsten Anne Armstrong; Scott Bryan Campbell; Nicole Maree Isbel; Carmel Mary Hawley Journal: Kidney Int Date: 2005-02 Impact factor: 10.612
Authors: Alfred K Cheung; Mark J Sarnak; Guofen Yan; Michael Berkoben; Robert Heyka; Allen Kaufman; Julia Lewis; Michael Rocco; Robert Toto; David Windus; Daniel Ornt; Andrew S Levey Journal: Kidney Int Date: 2004-06 Impact factor: 10.612
Authors: Umesh U Tamhane; Sanjay Aneja; Daniel Montgomery; Eva-Kline Rogers; Kim A Eagle; Hitinder S Gurm Journal: Am J Cardiol Date: 2008-06-26 Impact factor: 2.778
Authors: Adelaide M Arruda-Olson; Guy S Reeder; Malcolm R Bell; Susan A Weston; Véronique L Roger Journal: Circ Cardiovasc Qual Outcomes Date: 2009-09-01
Authors: Adrian Vasile Mureșan; Eliza Russu; Emil Marian Arbănași; Réka Kaller; Ioan Hosu; Eliza Mihaela Arbănași; Septimiu Toader Voidăzan Journal: Biomedicines Date: 2022-05-29
Authors: Mustafa Yaprak; Mehmet Nuri Turan; Ramazan Dayanan; Selçuk Akın; Elif Değirmen; Mustafa Yıldırım; Faruk Turgut Journal: Int Urol Nephrol Date: 2016-04-27 Impact factor: 2.370